Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Olverembatinib · 4 trials · 7 indications
Proportion of subjects who do not experience disease progression or death after the first dose of treatment as assessed by Independent Review Committee.
| Arm | Type | Description |
|---|---|---|
| Olverembatinib | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| olverembatinib | DRUG | olverembatinib QOD |
| Bosutinib | DRUG | Bosutnib QD |
| Imatinib | DRUG | Orally, once daily (QD). |
| Olverembatinib 20mg | DRUG | orally after meal, single dose |
Inclusion Criteria: 1. Histologically and/or cytologically confirmed GIST, immunohistochemistry with loss of SDHB expression, and failure of at least one prior systemic therapy. Defined as disease progression or intolerable as judged by the investigator. 2. Must have at least one measurable target ...